Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling

Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling

Buprenorphine readily crosses the placenta, and with greater prenatal exposure, neonatal opioid withdrawal syndrome (NOWS) likely grows more severe. Current dosing strategies can be further improved by tailoring doses to expected NOWS severity. To allow the conceptualization of fetal buprenorphine e...

Description complète

Détails bibliographiques
Auteurs principaux: Matthijs W. van Hoogdalem, Ryota Tanaka, Khaled Abduljalil, Trevor N. Johnson, Scott L. Wexelblatt, Henry T. Akinbi, Alexander A. Vinks, Tomoyuki Mizuno
Format: Article
Langue:English
Publié: MDPI AG 2024-03-01
Collection:Pharmaceutics
Sujets:
buprenorphine
maternal–fetal
physiologically based pharmacokinetic modeling
neonatal opioid withdrawal syndrome
opioid use disorder
Accès en ligne:https://www.mdpi.com/1999-4923/16/3/375

Internet

https://www.mdpi.com/1999-4923/16/3/375

Documents similaires